KADIMASTEM LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 494.7 ILa | +1.33% |
|
+7.17% | -16.58% |
| Mar. 28 | Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 28 | IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 72.68 | 54.53 | 39.65 | 118.1 | 40.08 | 24.87 |
| Enterprise Value (EV) 1 | 62.1 | 64.27 | 47.18 | 100.8 | 40.82 | 27.04 |
| P/E ratio | -2.06 x | -2.06 x | -1.39 x | -3.16 x | -1.76 x | -2.09 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -2.68 x | -2.66 x | -2.39 x | -4.39 x | -1.99 x | -2.54 x |
| EV / FCF | -4.91 x | -5.14 x | -3.33 x | -7.62 x | -3.19 x | -3.77 x |
| FCF Yield | -20.4% | -19.5% | -30% | -13.1% | -31.4% | -26.6% |
| Price to Book | 10.8 x | -4.53 x | -4.92 x | 7.68 x | 128 x | -5.7 x |
| Nbr of stocks (in thousands) | 945 | 1,025 | 1,944 | 3,365 | 3,488 | 4,194 |
| Reference price 2 | 76.90 | 53.20 | 20.40 | 35.10 | 11.49 | 5.930 |
| Announcement Date | 3/28/19 | 3/31/20 | 3/25/21 | 3/29/22 | 3/29/23 | 3/28/24 |
1ILS in Million2ILS
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -23.18 | -24.16 | -19.77 | -22.93 | -20.54 | -10.66 |
| EBIT 1 | -23.62 | -24.7 | -20.29 | -24.3 | -22.01 | -11.04 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -24.02 | -25.27 | -21.96 | -26.72 | -22.88 | -12.21 |
| Net income 1 | -23.97 | -25.09 | -21.71 | -26.28 | -22.72 | -12.01 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -37.30 | -25.87 | -14.72 | -11.10 | -6.515 | -2.840 |
| Free Cash Flow 1 | -12.64 | -12.51 | -14.17 | -13.22 | -12.81 | -7.18 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/28/19 | 3/31/20 | 3/25/21 | 3/29/22 | 3/29/23 | 3/28/24 |
1ILS in Million2ILS
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 9.74 | 7.53 | - | 0.74 | 2.17 |
| Net Cash position 1 | 10.6 | - | - | 17.3 | - | - |
| Leverage (Debt/EBITDA) | - | -0.4032 x | -0.381 x | - | -0.036 x | -0.2036 x |
| Free Cash Flow 1 | -12.6 | -12.5 | -14.2 | -13.2 | -12.8 | -7.18 |
| ROE (net income / shareholders' equity) | -435% | 949% | 216% | -718% | -289% | 595% |
| ROA (Net income/ Total Assets) | -110% | -141% | -140% | -79.7% | -69.1% | -66.2% |
| Assets 1 | 21.72 | 17.79 | 15.48 | 32.99 | 32.89 | 18.15 |
| Book Value Per Share 2 | 7.130 | -11.70 | -4.150 | 4.570 | 0.0900 | -1.040 |
| Cash Flow per Share 2 | 11.80 | 0.0400 | 2.790 | 6.920 | 1.760 | 0.9900 |
| Capex 1 | 0.79 | 0.74 | 0.16 | 0.54 | 0.64 | 0.02 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/28/19 | 3/31/20 | 3/25/21 | 3/29/22 | 3/29/23 | 3/28/24 |
1ILS in Million2ILS
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -16.58% | 5.44M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- KDST Stock
- Financials Kadimastem Ltd
